The H3 Biomedicine RNA splicing modulator, H3B-8800 , targets the spliceosome SF3b complex containing either wild-type (WT) or mutant SF3B1. Splicesome inhibition can induce synthetic lethality since cancer cells bearing spliceosome mutations are more dependent on WT spliceosome function. The compound is derived from the natural product [...]
< 1 minute read
Feb. 9, 2022
H3B-8800: an H3 Biomedicine RNA Splicing Modulator
H3Bio SF3b Splicing Modulator
oral splicing modulator (SF3b complex) 7-20 mg 21d+/7d-, Ph. I for myeloid neoplasias from opt. of pladienolide B natural product H3B-8800 H3 Biomedicine, Cambridge, MA